Other novel immunotherapy strategies have also been evaluated for complimentary effects to BRAF inhibitors, including oncolytic HSV [105] and CAR T-cell therapy [106], both of were shown to enhance tumor control in pre-clinical models. Here, BRAF is linked to neoplasm.